

1

2 **Rapid and accurate point-of-care testing for SARS-CoV2 antibodies**

3

4 Sally Esmail<sup>1</sup>, Michael J. Knauer<sup>2</sup>, Husam Abdoh<sup>2</sup>, Benjamin Chin-Yee<sup>3</sup>, Peter Stogios<sup>5</sup>,  
5 Almagul Seitova<sup>4</sup>, Ashley Hutchinson<sup>4</sup>, Farhad Yusifov<sup>4</sup>, Tatiana Skarina<sup>5</sup>, Elena  
6 Evdokimova<sup>5</sup>, Suzanne Ackloo<sup>4</sup>, Lori Lowes<sup>2</sup>, Courtney Voss<sup>1</sup>, Benjamin D. Hedley<sup>2</sup>, Vipin  
7 Bhayana<sup>2</sup>, Ian Chin-Yee<sup>2</sup> and Shawn S-C. Li<sup>1\*</sup>

8

9 <sup>1</sup>Departments of Biochemistry, Schulich School of Medicine and Dentistry, Western  
10 University, London, Ontario N6G 2V4, Canada;

11 <sup>2</sup>Department of Pathology and Laboratory Medicine and <sup>3</sup>Divison of Hematology, Western  
12 University and London Health Sciences Centre, 800 Commissioners Rd E, London, Ontario  
13 N6A 5W9, Canada;

14 <sup>4</sup>Structural Genomics Consortium, University of Toronto, 101 College St, MaRS South  
15 Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada;

16 <sup>5</sup>Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200  
17 College St., Toronto, Ontario M5S 3E5, Canada.

18

19

20 \*Corresponding author: [sli@uwo.ca](mailto:sli@uwo.ca)

21

22

23

24 **ABSTRACT**

25

26 The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2  
27 (SARS-CoV-2), has grown into worst public health crisis since the 1918 influenza pandemic.  
28 As COVID-19 continues to spread around the world, there is urgent need for a rapid, yet  
29 accurate antibody test to identify infected individuals in populations to inform health  
30 decisions. We have developed a rapid, accurate and cost-effective serologic test based on  
31 antibody-dependent agglutination of antigen-coated latex particles, which uses ~5 µl plasma  
32 and takes <5 min to complete with no instrument required. The simplicity of this test makes it  
33 ideal for point-of-care (POC) use at the community level. When validated using plasma  
34 samples that are positive or negative for SARS-CoV-2, the agglutination assay detected  
35 antibodies against the receptor-binding domain of the spike (S-RBD) or the nucleocapsid (N)  
36 protein of SARS-CoV-2 with 100% specificity and ~98% sensitivity. Furthermore, we found  
37 that the strength of the S-RBD antibody response measured by the agglutination assay  
38 correlated with the efficiency of the plasma in blocking RBD binding to the angiotensin  
39 converting enzyme 2 (ACE2) in a surrogate neutralization assay, suggesting that the  
40 agglutination assay may be used to identify individuals with virus-neutralizing antibodies.  
41 Intriguingly, we found that >92% of patients had detectable antibodies on the day of positive  
42 viral RNA test, suggesting that seroconversion may occur earlier than previously thought and  
43 that the agglutination antibody test may complement RNA testing for POC diagnosis of  
44 SARS-CoV-2 infection.

45

## 46 INTRODUCTION

47

48 Development of rapid point-of-care COVID-19 diagnostics for use at the community level  
49 remains a top priority in the global response to the COVID-19 pandemic<sup>1</sup>. While capacity for  
50 detecting SARS-CoV-2 based on nucleic acid amplification (NAAT) has grown immensely  
51 and enabled effective public health responses, serologic testing for virus specific antibodies  
52 has not gained the same widespread application, due to concerns over sensitivity, specificity,  
53 cost and turn-around time<sup>1,2</sup>. Although NAAT is the current gold standard for diagnosing  
54 acute infection, it is not effective in identifying individuals who have recovered from  
55 previous infection<sup>3</sup>. Given that approximately 40% of infected individuals remain  
56 asymptomatic<sup>1,4,5</sup>, large-scale antibody testing could help better establish the true extent of  
57 the COVID-19 pandemic, identifying disease hotspots and high-risk populations to enable  
58 more effective isolation and contact tracing<sup>1,3,6</sup>. Moreover, antibody testing may identify  
59 individuals with a strong neutralizing antibody response who may be suitable donors for  
60 convalescent plasma/serum therapy for the treatment of those with severe symptoms<sup>7</sup>.

61

62 To date, a number of antibody tests have been approved for emergency use in the US and  
63 Europe. These tests detect the IgG, IgM or IgA antibody against the spike (including the  
64 receptor binding domain, RBD) or nucleocapsid (N) protein of the SARS-CoV-2 virus by  
65 enzyme-linked immunosorbent assay (ELISA)<sup>3</sup>. ELISA-based antibody tests, which can be  
66 qualitative or quantitative, require specialized instruments and are usually performed in a lab  
67 by a trained technician. The sensitivity and specificity of different ELISA kits vary widely<sup>8-10</sup>.  
68 To enable point-of-care (POC) testing, several rapid diagnostic tests (RDTs) based on lateral  
69 flow have been developed. Although the RDTs reduced the time of the antibody test to 10-30  
70 minutes from 2-5 hours (for ELISA), they generally suffer from decreased sensitivity and  
71 specificity compared to ELISA-based assays<sup>1,11-13</sup>.

72

73 To address the pressing need for a simple, rapid, yet accurate antibody test<sup>1</sup>, we resorted to the  
74 tested-and-proven serology method of agglutination that has been used in blood typing and  
75 antibody testing<sup>14-16</sup>. We show here that the agglutination of red blood cells (RBCs) or latex  
76 particles induced by specific antigen-antibody interaction affords a highly sensitive and  
77 accurate assay for SARS-CoV-2 antibodies. We validated the antibody assay based on latex  
78 particle agglutination using 169 plasma samples that were tested positive for SARS-CoV-2 by

79 NAAT, 121 samples that were NAAT negative and 100 SARS-CoV-2 naïve plasma samples.  
80 The agglutination-based antibody assay produced 100% specificity and 97-98.2% sensitivity.  
81 Because this simple assay requires no instrument and generates results in 2 minutes, it has the  
82 potential to be used as a POC or at-home test.

83

## 84 **RESULTS**

85

### 86 **Agglutination-based serologic testing for SARS-CoV-2 antibodies**

87

88 Agglutination of RBCs is widely used in blood typing whereas latex particle agglutination  
89 assays have been used to detect antibodies against a variety of different viruses. We sought to  
90 establish whether either or both approaches could be adapted for SARS-CoV-2 antibody  
91 testing. In principle, coating the RBCs or the latex particles with a SARS-CoV-2 specific  
92 antigen would enable their respective agglutination by the corresponding antibody (Fig. 1).  
93 To explore this notion, we labelled Group O (R2R2) RBCs carrying the D antigen with the  
94 spike RBD (S-RBD) or the RNA binding domain of the nucleocapsid (N-RBD) protein  
95 through streptavidin-biotin mediated coupling (Figs. S1 & S2, see Materials and Methods for  
96 details). Incubating the antigen-coated RBCs with COVID-19<sup>+</sup> plasma led to robust  
97 agglutination whereas the COVID-19<sup>-</sup> plasma failed to induce RBC agglutination, suggesting  
98 that the aggregation of the S-RBD/N-RBD-coated RBCs may be used to detect antibody  
99 response to SARS-CoV-2 (Fig. S2).

100

101 To develop a cost-effective agglutination assay, we next investigated if latex particles were a  
102 suitable substitute for the RBCs. To this end, we coated latex particles with recombinant  
103 S-RBD or the full-length nucleocapsid (N) protein (Fig. S1). The antigen coated latex beads  
104 were first tested with a monoclonal anti-S-RBD and a polyclonal anti-nucleocapsid antibody.  
105 Upon incubating with the corresponding antibody, the antigen-coated latex particles formed  
106 clumps within two minutes. Importantly, the area of clump formation grew larger with  
107 increasing antibody concentrations (Fig. S3). Although latex agglutination was commonly  
108 used as a qualitative assay, it is possible to determine the degree of agglutination based on the  
109 area of clump formation via image analysis. As shown in Fig. 2, the percentage of  
110 agglutination for both the S-RBD- and N-coated latex particles increased when an  
111 incremental amount of anti-S-RBD or anti-N antibody was added. Fitting the data to Hill's

112 equation yielded Hill's coefficient of 1.7 for the former and 1.8 for the latter. This suggests  
113 that the antibody-induced agglutination of latex particles is a cooperative event (Fig. 2A&B).

114

115 We next examined if the latex agglutination assay could be used to gauge COVID-19  
116 antibody response. Using plasma samples from patients tested positive for SARS-CoV-2 by  
117 NAAT and confirmed for strong antibody response by ELISA, we found that the patient  
118 plasma samples were not only capable of inducing agglutination of the S-RBD- or N-coated  
119 latex particles, they did so in a concentration-dependent manner. As shown in Fig. 2C&D, the  
120 extent of agglutination decreased as the plasma was diluted, indicating that the agglutination  
121 assay may be used to estimate antibody titer as in an ELISA-based antibody test.

122

### 123 **The latex agglutination-based antibody assay showed high sensitivity and specificity**

124

125 To validate the antibody test based on latex particle agglutination, we carried out  
126 agglutination assays for 290 residual plasma samples from individuals that were tested  
127 positive (169) or negative (121) for virus RNA by the Roche cobas SARS-CoV-2 test<sup>9</sup>. To  
128 assess specificity, we also included 100 virus-naïve samples banked in 2018 in our  
129 agglutination assay. None of the 121 SARS-CoV-2<sup>-</sup> or the 100 Pre-COVID-19 plasma  
130 samples was capable of promoting the agglutination of either the S-RBD- or N-coated latex  
131 particles, indicating 100% specificity for the agglutination assay (Table 1). In contrast, of the  
132 169 SARS-CoV-2<sup>+</sup> plasma samples tested, 166 (98.2%) promoted agglutination in response  
133 to the S-RBD antigen and 164 (97%) to the N antigen, with overall sensitivity of 98.2%. We  
134 compared the latex agglutination assay with the Euroimmune IgG test for the S antibody and  
135 the Roche Elecsys® Total assay for the N antibody using the same set of SARS-CoV-2<sup>+</sup>  
136 plasma samples and found that the latex agglutination assay outperformed both ELISA-based  
137 antibody tests (Table 2). The agglutination assay also exhibited better specificity than either  
138 ELISA kit (Table 2). Quantification of the agglutination data showed that the COVID-19<sup>+</sup>  
139 group is significantly different from the COVID-19<sup>-</sup> or pre-COVID-19 group, indicating that  
140 the latex agglutination assay effectively distinguished SARS-CoV2<sup>+</sup> from SARS-CoV2<sup>-</sup>  
141 individuals (Fig. 3A&B).

142

143 Based on the background signals of the COVID-19<sup>-</sup> samples (0-4% agglutination for both  
144 S-RBD- and N-coated latex particles), we set 5% agglutination as the cut-off for antibody  
145 positivity. To facilitate the use of the latex agglutination assay as a simple, semi-quantitative

146 antibody test, we developed a numerical scoring system for antibody response. We assigned  
147 the scores 1, 2, 3 and 4 to samples that produced 5-25%, 25-50%, 50-75% and >75%  
148 agglutination, respectively (Fig. S4). We found that this scoring scheme effectively  
149 distinguished samples with strong antibody response from those with medium or weak ones  
150 (Fig. 3C&D). The agglutination score may be readily assigned by visual inspection and  
151 comparing to reference wells containing a predetermined amount of pure anti-S-RBD or  
152 anti-N antibody (Fig. S3).

153

#### 154 **The S-RBD antibody response correlated with neutralizing antibody titer**

155

156 Because neutralizing antibodies (Nab) play a pivotal role in the humoral immune response to  
157 the virus<sup>17</sup>, we next examined if the S-RBD antibody response determined by the  
158 agglutination assay correlated with neutralization efficiency. We developed a surrogate  
159 neutralization assay by measuring the efficacy of patient plasma in blocking S-RBD binding  
160 to its host receptor, angiotensin converting enzyme 2 (ACE2) *in vitro*. Similar approaches  
161 have been used by others to evaluate neutralization efficiency of patient plasma or therapeutic  
162 antibodies<sup>18,19</sup>. Briefly, binding of biotinylated ACE2 to immobilized S-RBD is detected by  
163 ELISA through HRP-conjugated streptavidin. The presence of neutralizing antibody would  
164 block this interaction, resulting in reduction of the ELISA signal. Using this surrogate  
165 neutralization assay, we found that the neutralization efficiency increased with the  
166 agglutination score for the S-RBD antibody (Fig. 4A). Intriguingly, comparison of samples  
167 with distinct S-RBD and N antibody responses indicated that the neutralization efficiency  
168 was significantly correlated with the S-RBD, but not the N antibody strength. This is not  
169 surprising given that the nucleocapsid is not involved in mediating virus entry into the host  
170 cells via ACE2. Nevertheless, it remains to be determined if the plasma with strong N  
171 antibody response would confer immunity by inhibiting virus replication *in vivo*.

172

#### 173 **The agglutination assay allowed for early antibody detection and tracking of dynamic** 174 **antibody response**

175

176 We noted that the agglutination assay detected antibody response in >92% plasma samples  
177 collected on the day of SARS-CoV2<sup>+</sup> diagnosis by NAAT and in 100% samples on day 2 and  
178 afterward. This is in stark contrast to the 47% to 83% sensitivity for ELISA-based antibody  
179 tests on samples collected within 7 days of positive NAAT<sup>9</sup>. The superb sensitivity of the

180 latex agglutination assay suggests that it may be used to detect antibody response in the early  
181 stage of virus infection and monitor its dynamic changes over time<sup>12,20,21</sup>. Using serial blood  
182 samples from SARS-CoV-2<sup>+</sup> patients, we compared the changes in the S-RBD and N  
183 antibody responses between days 1 and day 3 (Fig. 4C&D). We found that the majority of  
184 patients showed detectable S-RBD and/or N antibodies on NAAT<sup>+</sup> day 1. Moreover, the  
185 antibody titer increased significantly on day 3 compared to day 1. Because it is not possible  
186 to determine how long these patients had contracted the virus prior to the NAAT test,  
187 seroconversion might have occurred for some on the day of diagnosis. Nevertheless, we were  
188 able to detect anti-S-RBD or anti-N antibodies on day 3 for several patients who showed no  
189 detectable antibody on day 1, suggesting seroconversion occurred rapidly in these patients<sup>4</sup>.  
190 Taken together, these data suggest that the latex agglutination assay may be used to diagnose  
191 active infection in conjunction with NAAT. Combined antibody and RNA testing may  
192 increase the sensitivity of the later. Moreover, the agglutination-based antibody test may be  
193 used to monitor the evolution of humoral immune reaction in infected individuals over  
194 time.

195

## 196 **DISCUSSION**

197

198 Antibody testing offers an additional and much needed tool for managing the COVID-19  
199 pandemic, which may allow for rapid and cost-effective POC diagnosis to facilitate treatment  
200 and public health responses. Furthermore, antibody testing may play an important role in  
201 identifying individuals who have gained protective immunity from previous exposure or  
202 immunization programs. While the clinical trial results for several vaccine candidates are  
203 encouraging, seroconversion is unlikely to occur for all vaccinated individuals<sup>22</sup>. A highly  
204 sensitive and specific antibody test would allow for accurate assessment of humoral response  
205 to a vaccine, and serial testing post-vaccination could indicate the duration of humoral  
206 immunity against SARS-CoV-2. Such information will be invaluable to inform public health  
207 decisions, both for directing resource allocation and determining response to vaccination.

208

209 While most serology tests used in the clinic are specific for a specific antibody isoform, IgG,  
210 IgM or IgA, the latex agglutination antibody assay is, in principle, isotope-independent<sup>11</sup>.  
211 This may contribute to its high sensitivity, especially on samples collected in the early phase  
212 of infection when IgG isotope switching has not yet occurred. It has been shown that the IgM  
213 antibody response proceeds that of IgG<sup>3,11</sup>, and the pentameric architecture of IgM may make

214 it a stronger promoter of agglutination than IgG. Moreover, the agglutination assay detects  
215 antibodies against the spike (S) and the nucleocapsid (N) in parallel whereas most existing  
216 assays are specific for either protein. These factors explain why the agglutination assay could  
217 detect antibody in >92% plasma samples collected on the day of NAAT<sup>+</sup> diagnosis and 100%  
218 on day 2 and onwards whereas other antibody tests were less sensitive. The ability of our  
219 assay to detect antibodies at the early stages of infection suggests that it may be used to  
220 complement or confirm the diagnosis based on NAAT, which is prone to false positives or  
221 false negatives especially when done only once<sup>23</sup>.

222

223 Several features of the agglutination assay make it an ideal candidate for POC or at-home  
224 antibody testing. First, the assay is highly sensitive and accurate, with 100% specificity and  
225 ~98% sensitivity on the samples tested in this study. Importantly, it detected antibodies in >92%  
226 COVID-19 patients on the day of diagnosis. This sensitivity rivals that of NAAT tests<sup>23</sup>.  
227 Second, the agglutination test is fast. It takes two minutes from mixing the plasma with the  
228 latex particles to getting the result. Third, the agglutination assay is simple to run and  
229 instrument-free. As the formation of latex bead clumps is easy to identify by the naked eye, the  
230 test may be performed without extensive specialized training. Fourth, because the  
231 agglutination assay takes only ~5 µl plasma, it may be developed into a finger prick blood test  
232 suitable for at-home use. Finally, the low cost of the latex agglutination assay makes it  
233 universally affordable and ideal for antibody testing at the community or population level, in  
234 high- and low-resource settings alike.

235

## 236 **ACKNOWLEDGEMENT**

237

238 We thank the Center for Structural Genomics of Infectious Diseases (CDGID) for the N-RBD  
239 expression plasmid, Dr. Jason McLellan for expression plasmid for human ACE2, Dr. Shane  
240 Harding for the spike-receptor binding domain expression construct, and Yanjun Li for  
241 technical assistance. This work was supported by a grant (to SSCL, ICY, MK, BCY and VB)  
242 from the Ontario Research Fund-COVID-19 Rapid Research Fund and by the Toronto  
243 COVID-19 Action Fund. SE was supported by a Post-Doctoral Fellowship from the National  
244 Science and Engineering Council of Canada. SSCL held a Canada Research Chair in  
245 Molecular and Epigenetic Basis of Cancer.

247 **Table 1: Clinical performance of the agglutination-based antibody assay**

248

Samples	Anti-S-RBD (n)		Anti-N (n)		Overall Sensitivity	Overall Specificity
	Positive	Negative	Positive	Negative		
SARS-CoV-2 NAAT positive (n=169)	166	3	164	5	<b>98.2%</b> (166/169)	
<b>Days of SARS-CoV-2 NAAT positive</b>						
1 (n=41)	38	3	36	5	92.7% (38/41)	
2 (n=31)	30	1	31	0	100%	
≥3 (n=97)	97	0	96	1	100%	
<b>SARS-CoV-2 NAAT negative (n=121)</b>	0	121	0	121		<b>100%</b>
<b>Pre-COVID-19 (n=100)</b>	0	100	0	100		100%

249

250 **Table 2: Comparison in sensitivity and specificity between the agglutination-based**  
 251 **and ELISA-based antibody assays**  
 252

Anti-S (RBD)	Agglutination assay (n)		ELISA <sup>9</sup> EUROIMMUNE (n)		Sensitivity (Agglutination)	Sensitivity (Euroimmune)	Specificity (Agglutination)	Specificity (Euroimmune)
	Positive	Negative	Positive	Negative				
SARS-CoV-2 NAAT positive (n=121)	118	3	90	31	<b>97.5%</b> (118/121)	<b>74.4%</b> (90/121)	NA	
SARS-CoV-2 NAAT Negative & preCOVID-19	0	221	11	194	NA		<b>100%</b> (221/221)	<b>94.6%</b> (194/205)
Anti-N	Agglutination assay (n)		ELISA <sup>9</sup> Roche Elecsys® (n)		Sensitivity (Agglutination)	Sensitivity (Roche)	Specificity (Agglutination)	Specificity (Roche)
	Positive	Negative	Positive	Negative				
SARS-CoV-2 NAAT positive (n=69)	68	1	66	2	<b>98.6%</b> (68/69)	<b>95.7%</b> (66/69)	NA	
SARS-CoV-2 NAAT Negative & preCOVID-19	0	221	1	135	NA		<b>100%</b> (221/221)	<b>99%</b> (135/136)

253

254

255

256

257 **FIGURE LEGENDS**

258

259 **Figure 1. Illustration of the principle of agglutination assay for SARS-CoV-2 antibody**

260 **testing.** (A) Latex particles or red blood cells (RBCs) are surface-coated with a SARS-CoV-2  
261 antigen, the S-RBD or nucleocapsid (N). Incubation with plasma containing antibodies  
262 against the coated antigen would induce agglutination of the latex particles or RBCs. (B) A  
263 representative image of the agglutination assay using latex beads coated with S-RBD.

264

265 **Figure 2. Antibody-induced latex particle agglutination correlates with the antibody**  
266 **titer.**

267 (A, B) Changes in agglutination in response to increased concentrations of the anti-S-RBD  
268 (n=3) or anti-N antibody (n=3). Dash lines represent fitted curves to Hill equation (h, Hill  
269 coefficient). (C, D) S-RBD (C) or N (D) antibody-induced agglutination decreased with  
270 increased dilution of plasma. Shown are agglutination data (in log<sub>2</sub> scale) from three  
271 COVID-19<sup>+</sup> plasma samples with 1:2 to 1:128 dilution (three replicates/concentration).

272

273 **Figure 3. Agglutination assay distinguished COVID-19<sup>+</sup> from COVID-19<sup>-</sup> samples.**

274 (A, B) Comparison of S-RBD (A) and N antibody responses between COVID-19<sup>+</sup> (n=169),  
275 COVID-19<sup>-</sup> (n=121) and Pre-COVID-19 (n=100) samples determined by the aggregation  
276 assay. (C, D) The strength of the S-RBD and N antibody response in the COVID-19<sup>+</sup> (n=169)  
277 plasma samples could be determined semi-quantitatively by the aggregation score (1-4  
278 denotes weak-to-strong antibody response). Statistical analyses were performed using  
279 unpaired Student's t-test with Welch's correction (p values shown on graph).

280

281 **Figure 4. Using the latex agglutination assay to determine neutralizing antibody titer**  
282 **and dynamic changes in antibody response.** (A) Neutralization antibody response

283 correlated significantly with the agglutination score. P values calculated based on unpaired  
284 Student t-test (n=10 for each group). (B) Spearman (r) correlation of efficiency of  
285 neutralization and S-RBD or N antibody response (n=25). (C, D) Dynamic changes in

286 antibody responses in COVID-19 patients. n=20 for day 1 and n=20 for day 3; p-values  
287 calculated based on unpaired Student's t-test with Welch's correction.

## 288 **MATERIALS AND METHODS**

### 289 **Blood sample collection**

290 Blood samples were collected following a protocol (study number: 116284) approved by the  
291 Research Ethics Board (REB) of Western University. The plasma samples were de-identified  
292 prior to transfer from the Laboratory of Clinical Medicine (London Health Sciences Center,  
293 London, Canada) to a biosafety Level 3 (CL3) lab (ImPaKT, Western University) following  
294 Transportation of Dangerous Goods (TDG) guidelines. All plasma samples were  
295 heat-inactivated at 56 °C for 30 minutes at the ImPaKT CL3 facility as per Western university  
296 biosafety regulation. Heat inactivated plasma samples were then transferred to the testing  
297 laboratory. We tested the effect of heat inactivation on SARS-CoV-2 antibody titer and found  
298 no significant impact of heat-inactivation (see also Fig. S5).

### 299 **Recombinant protein production and purification**

300 The expression plasmid for human ACE2 cloned into the mammalian expression vector pαH  
301 (residues 1–615 with a C-terminal HRV3C protease cleavage site, a TwinStrepTag and an  
302 8XHisTag) was a generous gift by Dr. McLellan. SARS-CoV-2 S-RBD cloned into pCAGGs  
303 the expression vector was received from Dr. Harding's lab. SARS-CoV-2 N-RBD was cloned  
304 into the pMCSG53 prokaryotic expression vector (residues 47-173-terminal 6x-His tag + TEV  
305 protease cleavage site).

306

307 Recombinant ACE2 and S-RBD proteins were produced by transient transfection of Expi293F  
308 cells (ThermoFisher Scientific, A14527) with a corresponding expression vectors and  
309 FectoPRO® DNA transfection reagent (Polyplus-transfection® SA, Cat. #116-010).  
310 Supernatants from transfected cells were harvested after 96 hours of the post-transfection time  
311 by centrifugation of the culture at 65,000 RPM for 30 min at 4°C. Cleared supernatant was then  
312 incubated with 4 ml TALON® Metal Affinity Resin (Takara Bio USA, Inc. Cat#635652) for 2h  
313 at 4°C. Ni-NTA chromatography was used to purify His-tagged recombinant proteins. Each  
314 protein was dialyzed and concentrated in Amicon centrifugal units (EMD Millipore) in a final

315 buffer of 20mM HEPES (pH 7.5, 200mM NaCl, pH 7.5, 5% glycerol).

316

317 Recombinant N-RBD was expressed in *E. coli* BL21(DE3)-Gold. Ni-NTA chromatography  
318 and size exclusion chromatography-Superdex S200 was used to purify N-RBD. The tag was  
319 cleaved using TEV followed by dialysis. The N-RBD protein was resuspended in 0.1 M NaCl,  
320 20 mM HEPES pH 7.5 and stored at -80 °C until use. Recombinant nucleocapsid (residues  
321 1-419) was obtained from RayBiotech (Cat #230-01104). Protein purity was confirmed by  
322 SDS-PAGE (Fig. S1).

### 323 **Preparation of SARS-CoV-2 antigen coated latex particles**

324 Blue dyed polystyrene latex beads, 0.8  $\mu$ m in diameter, were purchased from Sigma Aldrich  
325 (L1398). Prior to use, the latex beads were washed according to the manufacturer's  
326 instructions with some modifications. Briefly, 2.5mL of 5% (w/v) latex suspension was  
327 washed twice in 10 mL PBS buffer (135 mM NaCl, 2.6 mM KCl, 8 mM Na<sub>2</sub>HPO<sub>4</sub>, and 1.5  
328 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) by mixing and centrifuging the latex suspension at 3,000g for 10  
329 minutes at room temperature. The beads were then resuspended with 2.5 ml 0.025M MES  
330 buffer (2-(N-Morpholino) ethanesulfonic acid, pH 6.0) to obtain 5% (w/v) suspension.

331

332 SARS-CoV-2 antigen-latex particle conjugates were prepared by passive adsorption  
333 following the procedures described by Mahat et al<sup>24</sup>, with some modifications. Briefly, 0.4  
334 mL of 5% (w/v) latex suspension was centrifuged at 3,000 g for 5 minutes at room  
335 temperature, and the supernatant was discarded. The beads were incubated with 200  $\mu$ g  
336 recombinant Receptor Binding Domain of the SARS-CoV-2 spike protein (S-RBD)  
337 (Structural Genomics Consortium, University of Toronto) or the Nucleocapsid protein (N  
338 protein) (RayBiotech, 230-01104) in 4 mL MES buffer. The mixture was allowed to incubate  
339 for 24 hours at 4°C with periodic mixing. After conjugation, the antigen-latex bead conjugate  
340 was centrifuged, and the supernatant was kept for determination of unabsorbed protein  
341 concentration (Bio-Rad protein assay kit). The antigen-bead conjugate was washed twice  
342 with PBS and blocked for 30 min at room temperature in PBS containing 3% bovine serum  
343 albumin (BSA). The conjugate was then resuspended at 2.5% (w/v) in PBS containing 1%  
344 BSA and stored at 4°C until use.

345

### 346 **Agglutination assay for SARS-CoV-2 antibody testing and data interpretation**

347

348 For the agglutination assay, 5  $\mu$ l plasma was mixed with 25  $\mu$ l antigen-coated beads (2.5%,  
349 w/v) per assay. The agglutination was allowed to proceed for 2 min at room temperature  
350 before imaging with a camera. The relative degree of agglutination induced by the  
351 SARS-CoV-2 antibody was measured by the area of clump formation based on the  
352 corresponding image. Agglutination data analyses were performed using qualitative and  
353 semi-quantitative assessments. For semi-quantification of agglutination, the image analysis  
354 software Qupath (v0.1.2) was used (<https://qupath.github.io/>) and quantification was done by  
355 calculating the percentage of agglutination based on estimated agglutination/clumps area  
356 ( $\text{mm}^2$ ) relative to the total latex reaction area. In qualitative assessments, agglutination  
357 intensity was inspected visually, and agglutination score was assigned (i.e. 1, 2, 3 and 4).  
358 Specifically, 1 corresponds to small clumps with ~25% agglutination, 2 (~50% agglutination),  
359 3 (~75% agglutination), and 4 (large clumps that forms in less than 1 min with ~100%  
360 agglutination). Based on data from the COVID-19 negative samples (including NAAT  
361 negative and samples collected in 2018), the cut-off for positivity was set to 5% of  
362 agglutination.

### 363 **Preparation of red blood cells conjugated with SARS-CoV-2 antigen**

364 The recombinant spike receptor-binding domain (S-RBD) or the nucleocapsid RNA-binding  
365 domain (N-RBD) was conjugated in 30-fold molar excess biotin using EZ-Link  
366 Sulfo-NHS-LC-LC-Biotin (Thermo Scientific, A35358). Excess unbound biotin was removed  
367 using Zeba™ Spin Desalting Columns, 7KMWCO (Thermo Scientific, 89890). Anti-D-IgG  
368 was purified from Immucor Anti-D Series 4 (IgG & IgM monoclonal blend) by using protein  
369 A magnetic affinity purification (G8782, Promega). The purified anti-D-IgG was then  
370 concentrated (3mg/ml) and stored at 4 °C until use. Anti-D was then conjugated with  
371 streptavidin according to manufacturer instruction (ab102921, abcam).

372

373 Bioconjugation of Anti-D-IgG-streptavidin with Reagent Red Blood Cells (RRBC) [0.8%  
374 R2R2; blood group O; Rh/D-antigen+] (Ortho-Clinical Diagnostics SELECTOGEN,  
375 6902315) was done by incubating the anti-D-IgG-streptavidin with RRBC for 30 min at room  
376 temperature. The RRBC-anti-D-streptavidin complex was then washed twice with low ionic  
377 strength RBC diluent (MTS™ Diluent 2 PLUS; Micro Typing Inc., MTS9330S). The  
378 complex was centrifuged at 1000g for 2 min to remove unbound anti-D-IgG streptavidin and

379 was then resuspended in the same RBC diluent. RBC-anti-D-IgG-streptavidin was then  
380 conjugated with either biotin-S-RBD or biotin-N-RBD for 15 min at room temperature. The  
381 RRBC-anti-D-streptavidin-biotin-S-RBD/N-RBD was stored at 4 °C until use. The RRBC  
382 agglutination assay was carried out in the same way as for latex agglutination described  
383 above.

384

### 385 **S-RBD-ACE2 binding ELISA and surrogate neutralization assay**

386

387 *ELISA plate Coating and blocking* -S-RBD was dissolved (5 µg/ml) in Tris buffer saline (TBS)  
388 (20 mM Tris, 150 mM NaCl, pH7.4) and 100 µl of the S-RBD solution was added to each well  
389 of an ELISA plate and incubate at 4°C overnight with slow shaking. The antigen-coated wells  
390 were washed 3 times with TBS-tween (TBST) (20 mM Tris, 150 mM NaCl, 0.1% Tween 20).  
391 The S-RBD coated wells were blocked by 100 µl of the ChonBlock™ blocking/sample  
392 dilution ELISA buffer (Chondrex, Inc., 9068) for 1 hour at room temperature with slow  
393 shaking followed washing 3 times with TBST.

394 *ACE2:S-RBD binding assay*- ACE2 was biotinylated as described above. Biotin-ACE2  
395 (1µg/m) was added to S-RBD-coated plate after blocking and incubated for 1hour at room  
396 temperature. The wells were washed 3 times with TBST to remove unbound biotin-ACE2.  
397 Streptavidin-HRP (1000-fold dilution with Chonblock blocking buffer) was then added to each  
398 well and incubated for 1hour at room temperature. The wells were washed 3 times with TBST  
399 and TMB substrate (3,3',5,5'-Tetramethylbenzidine, Thermo Scientific, N301) was added for  
400 reaction development and 0.18 M H<sub>2</sub>SO<sub>4</sub> was used to stop reaction. Absorbance at 450nm was  
401 measured to detect the S-RBD bound ACE2.

402 *SARS-CoV-2 antibody neutralization assay*- Plasma was diluted 1:100 and incubated with  
403 S-RBD-coated wells (blocked) for 1hour at room temperature. The wells were washed three  
404 times with TBST. Biotin-ACE2 was then added to the wells and incubated for 1 hour at room  
405 temperature followed by washing, reaction development and detection as described above.

406

### 407 **Statistical analysis**

408

409 All statistical analyses were done using the GraphPad Prism9 software. Specifically, the Hill  
410 coefficient (h) was calculated from fitting agglutination data obtained using anti-S-RBD and  
411 anti-N antibodies to the Hill equation. COVID-19<sup>+</sup> samples with distinct agglutination scores

412 and COVID-19<sup>+</sup> samples were analyzed using unpaired t-test with Welch's correction (no  
413 assumption of equal SD between two groups). Changes in agglutination for samples before  
414 and after heat-inactivation were analyzed by paired t-test. Spearman's correlation rank was  
415 done to study correlation between antibody titter and ACE2:S-RBD neutralization efficiency.  
416  
417


418 **REFERENCE**

419


- 420 1 Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response. *The*  
421 *Lancet Infectious Diseases* **20**, e245-e249, doi:10.1016/s1473-3099(20)30517-x  
422 (2020).
- 423 2 Kruttgen, A. *et al.* Comparison of four new commercial serologic assays for  
424 determination of SARS-CoV-2 IgG. *J Clin Virol* **128**, 104394,  
425 doi:10.1016/j.jcv.2020.104394 (2020).
- 426 3 Ravi, N., Cortade, D. L., Ng, E. & Wang, S. X. Diagnostics for SARS-CoV-2  
427 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape.  
428 *Biosens Bioelectron* **165**, 112454, doi:10.1016/j.bios.2020.112454 (2020).
- 429 4 Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in  
430 humans. *Nat Med* **26**, 1033-1036, doi:10.1038/s41591-020-0913-5 (2020).
- 431 5 He X, L. E., Wu P *et al.* Temporal dynamics in viral shedding and transmissibility of  
432 COVID-19. *Nat Med* **26**, 672-675 (2020).
- 433 6 Weisberg, S. P. *et al.* Distinct antibody responses to SARS-CoV-2 in children and  
434 adults across the COVID-19 clinical spectrum. *Nat Immunol*,  
435 doi:10.1038/s41590-020-00826-9 (2020).
- 436 7 Shen, C. *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With  
437 Convalescent Plasma. *JAMA* **323**, 1582-1589, doi:10.1001/jama.2020.4783 (2020).
- 438 8 Jaaskelainen, A. J. *et al.* Performance of six SARS-CoV-2 immunoassays in  
439 comparison with microneutralisation. *J Clin Virol* **129**, 104512,  
440 doi:10.1016/j.jcv.2020.104512 (2020).
- 441 9 Knauer, M. J. *et al.* Interim analysis of the clinical performance of five SARS-Cov-2  
442 serology assays. *Clin Biochem*, doi:10.1016/j.clinbiochem.2020.09.002 (2020).
- 443 10 Lisboa Bastos, M. *et al.* Diagnostic accuracy of serological tests for covid-19:  
444 systematic review and meta-analysis. *BMJ* **370**, m2516, doi:10.1136/bmj.m2516  
445 (2020).
- 446 11 Pavlova, I. P., Nair, S. S., Kyprianou, N. & Tewari, A. K. The Rapid Coronavirus

- 447           Antibody Test: Can We Improve Accuracy? *Front Med (Lausanne)* **7**, 569,  
448           doi:10.3389/fmed.2020.00569 (2020).
- 449    12    Whitman, J. D. *et al.* Test performance evaluation of SARS-CoV-2 serological assays.  
450           *medRxiv*, doi:10.1101/2020.04.25.20074856 (2020).
- 451    13    Li, Z. *et al.* Development and clinical application of a rapid IgM-IgG combined  
452           antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*,  
453           doi:10.1002/jmv.25727 (2020).
- 454    14    Gupta, A. & Chaudhary, V. K. Whole-blood agglutination assay for on-site detection  
455           of human immunodeficiency virus infection. *J Clin Microbiol* **41**, 2814-2821,  
456           doi:10.1128/jcm.41.7.2814-2821.2003 (2003).
- 457    15    Hursh DA, A. A., Sun R, Iltis JP, Rice DH and Gleaves CA. Evaluation of a Latex  
458           Particle Agglutination Assay for the Detection of Cytomegalovirus Antibody in  
459           Patient Serum. *J. Clin. Microbiol*, 2878-2879 (1989).
- 460    16    Alves, D. *et al.* Rapid Gel Card Agglutination Assays for Serological Analysis  
461           Following SARS-CoV-2 Infection in Humans. *ACS Sens* **5**, 2596-2603,  
462           doi:10.1021/acssensors.0c01050 (2020).
- 463    17    Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and  
464           Other Human Coronaviruses. *Trends Immunol* **41**, 355-359,  
465           doi:10.1016/j.it.2020.03.007 (2020).
- 466    18    Tortorici MA, B. M., Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen  
467           J, Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker  
468           H, Zhou J, Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE,  
469           Kaiser H, Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C,  
470           Sprugasci N, Culap K, Benigni F, Abdelnabi R, Foo SC, Schmid MA, Cameroni E,  
471           Riva A, Gabrieli A, Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, Snell G,  
472           Corti D, Fink K, Veessler D. . Ultrapotent human antibodies protect against  
473           SARS-CoV-2 challenge via multiple mechanisms. *Science*, 2020 Sep 2024:eabe3354.  
474           doi: 2010.1126/science.abe3354. Epub ahead of print. PMID: 32972994. (2020).


- 475 19 Abe, K. T. *et al.* A simple protein-based surrogate neutralization assay for  
476 SARS-CoV-2. *JCI Insight* **5**, doi:10.1172/jci.insight.142362 (2020).
- 477 20 Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in  
478 Convalescent Individuals. *bioRxiv*, doi:10.1101/2020.05.13.092619 (2020).
- 479 21 Qu, J. *et al.* Profile of IgG and IgM antibodies against severe acute respiratory  
480 syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*, doi:10.1093/cid/ciaa489  
481 (2020).
- 482 22 Thanh Le, T. *et al.* The COVID-19 vaccine development landscape. *Nat Rev Drug*  
483 *Discov* **19**, 305-306, doi:10.1038/d41573-020-00073-5 (2020).
- 484 23 Jarrom, D. *et al.* Effectiveness of tests to detect the presence of SARS-CoV-2 virus,  
485 and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic  
486 review. *BMJ Evid Based Med*, doi:10.1136/bmjebm-2020-111511 (2020).
- 487 24 Mahat, M., Abdullah, W. Z. & Che Hussin, C. M. Conventional rapid latex  
488 agglutination in estimation of von Willebrand factor: method revisited and potential  
489 clinical applications. *Journal of immunology research* **2014** (2014).  
490  
491




**Figure 1: Illustration of the principle of agglutination assay for SARS-CoV-2 antibody testing.** (A) Latex particles or red blood cells(RBC) are surface-coated with a SARS-CoV-2 antigen, the S-RBD or nucleocapsid (N). Incubation with plasma containing antibodies against the coated antigen would induce agglutination of the latex particles or RBCs. (B) A representative image of the agglutination assay using latex beads coated with S-RBD.



**Figure 2. Antibody-induced latex particle agglutination correlates with the antibody titer.** (A, B) Changes in agglutination in response to increased concentrations of the anti-S-RBD ( $n=3$ ) or anti-N antibody ( $n=3$ ). Dash lines represent fitted curves to Hill equation ( $h$ , Hill coefficient). (C, D) S-RBD (C) or N (D) antibody-induced agglutination decreased with increased dilution of plasma. Shown are agglutination data (in log2 scale) from three COVID-19+ plasma samples with 1:2 to 1:128 dilution. Data shown are from three replicates per concentration.



**Figure 3. Agglutination assay distinguished COVID-19<sup>+</sup> from COVID-19<sup>-</sup> samples.** (A, B) Comparison of S-RBD (A) and N antibody responses between COVID-19<sup>+</sup> (n=169), COVID-19<sup>-</sup> (n=121) and Pre-COVID-19 (n=100) samples determined by the aggregation assay. (C, D) The strength of the S-RBD and N antibody response in the COVID-19<sup>+</sup> (n=169) plasma samples could be determined semi-quantitatively by the aggregation score (1-4 denotes weak-to-strong antibody response). Statistical analyses were performed using unpaired Student's t-test with Welch's correction (p values shown on graph).



**Figure 4. Using the latex agglutination assay to determine neutralizing antibody titer and dynamic changes in antibody response. (A)** Neutralization antibody response correlated significantly with the agglutination score. P values calculated based on unpaired Student t-test ( $n=10$  for each group). **(B)** Spearman ( $r$ ) correlation of efficiency of neutralization and S-RBD or N antibody response ( $n=25$ ). **(C, D)** Dynamic changes in antibody responses in COVID-19 patients.  $n=20$  for day 1 and  $n=20$  for day 3; p-values calculated based on unpaired Student's t-test with Welch's correction.

## Supplementary Figures

### **Rapid and accurate point-of-care testing for SARS-CoV2 antibodies**

Sally Esmail<sup>1</sup>, Michael J. Knauer<sup>2</sup>, Husam Abdoh<sup>2</sup>, Benjamin Chin-Yee<sup>3</sup>, Peter Stogios<sup>5</sup>, Almagul Seitova<sup>4</sup>, Ashley Hutchinson<sup>4</sup>, Farhad Yusifov<sup>4</sup>, Tatiana Skarina<sup>5</sup>, Elena Evdokimova<sup>5</sup>, Suzanne Ackloo<sup>4</sup>, Lori Lowes<sup>2</sup>, Courtney Voss<sup>1</sup>, Benjamin D. Hedley<sup>2</sup>, Vipin Bhayana<sup>2</sup>, Ian Chin-Yee<sup>2</sup> and Shawn S-C. Li<sup>1\*</sup>

<sup>1</sup>Departments of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario N6G 2V4, Canada;


<sup>2</sup>Department of Pathology and Laboratory Medicine and <sup>3</sup>Divison of Hematology, Western University and London Health Sciences Centre, 800 Commissioners Rd E, London, Ontario N6A 5W9, Canada;

<sup>4</sup>Structural Genomics Consortium, University of Toronto, 101 College St, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada;

<sup>5</sup>Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College St., Toronto, Ontario M5S 3E5, Canada.


\*Corresponding author: [sli@uwo.ca](mailto:sli@uwo.ca)

Esmail et al.



**Figure S1. SDS-PAGE images of recombinant SARS-CoV-2 proteins employed in the current study.**


Esmail et al.



**Figure S2. SARS-CoV2 antibody testing based on RBC agglutination.**


Red blood cells (RBC, group O; R2R2) carrying the D antigen were labelled with anti-D IgG conjugated to recombinant S-RBD or N-RBD through streptavidin-biotin (i.e., IgG-streptavidin conjugated to biotin-RBD). (A) S-RBD labeled RBCs were mixed with either SARS-CoV-2<sup>-</sup> (NAAT) or SARS-CoV2<sup>+</sup> plasma (right). (B) N-RBD labeled RBCs were mixed with either SARS-CoV2<sup>-</sup> (left) or SARS-CoV2<sup>+</sup> plasma (right). Images shown were taken after 1 min incubation at room temperature.

Esmail et al.




**Figure S3. Agglutination of blue latex particles in response to different concentrations of antibody (IgG) against the nucleocapsid (αN) or S-RBD (αS-RBD).** Anti-S-RBD (monoclonal, NBP2-90980) was obtained from Novus Biologicals; Anti-Nucleocapsid (polyclonal, PA5-81794) was from ThermoFisher Scientific.

Esmail et al.



**Figure S4. Representative images of agglutination induced by plasma with different agglutination scores.** Shown are five samples with distinct agglutination scores (0-4) in the nucleocapsid ( $\alpha N$ ) (upper row) or the S-RBD antibody ( $\alpha S-RBD$ ) test (lower row). The scores were assigned as 4 = 75-100% agglutination; 3 = 50-75% agglutination; 2 = 25-50% agglutination; 1 = 5-25% agglutination; 0 (or negative)  $\leq 5\%$  agglutination.

Esmail et al.



**Figure S5. Heat inactivation of plasma did not affect antibody induced agglutination.** Shown are agglutination percentages between samples without or with heat-inactivation in the anti-S-RBD (left) or anti-N (right) agglutination assay. p-values calculated from paired two tailed t-test (no assumption of equal variance, n=6).